Drug intelligence / Profile preview

Lactoral

Development stage
Unknown
Lead developer
Biomed
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Lactoral is a probiotic dietary supplement developed and manufactured by the Polish company Biomed (Instytut Biotechnologii Surowic i Szczepionek BIOMED Spółka Akcyjna). [1, 8] It is a biologic product consisting of three patented live bacterial strains: *Lactobacillus plantarum* PL02, *Lactobacillus rhamnosus* KL53A, and *Bifidobacterium longum* PL03. [1, 5] The product does not have a traditional single molecular target; instead, it works by colonizing the intestinal tract to regenerate and maintain the balance of the gut microbiome. [1] Its mechanisms include adhering to the intestinal epithelium, producing antimicrobial organic acids, inhibiting the growth of pathogenic bacteria and fungi, and enhancing the integrity of the intestinal barrier. [7, 8] Lactoral is intended for adults and children over 3 years old to restore the microbiome during and after antibiotic therapy, during periods of chronic stress, or with diet changes that cause dysbiosis. [1, 2] A variant, Lactoral IBD, is formulated for the dietary management of inflammatory bowel disease (IBD), particularly ulcerative colitis. [6, 12] The standard product is available in capsules containing approximately 2.8 billion colony-forming units (CFU), while Lactoral IBD contains 10 billion CFU. [3, 7]

Brand names
LactoralLactoral IBD

Beyond the preview

Go deeper on Lactoral.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactoral.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call